Cost-effectiveness findings not based on available evidence

• Pfizer Australia Pty Ltd, 38–42 Wharf Road, West Ryde, NSW 2114.

---

• 1. Segal L, Day SE, Chapman AB, Osborne RH. Can we reduce disease burden from osteoarthritis? An evidence-based priority-setting model. Med J Aust 2004; 180 (5 Suppl): S11-S17.
• 2. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095-1105.
• 3. Williams GW, Hubbard RC, Yu SS, et al. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of OA of the knee. Clin Ther 2001; 23: 213-227.
• 4. Juni P, Rutjes AW, Dieppe PA. Are selective COX2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? [editorial]. BMJ 2002; 324: 1287-1288.
• 5. Silverstein FE, Faich G, Goldstein JL. Gastrointestinal toxicity with celecoxib versus non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284: 1247-1255.
• 6. Silverstein F, Simon L, Faich G. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [letter]. JAMA 2001; 286 (19): 2399-2400.
• 7. Yeomars ND. Impact of cyclooxygenase-2 inhibitors: Are they fulfilling their promise [editorial]. Intern Med J 2004; 34: 145-147.
• 8. Grobler M, Schaffer D, Burke TA, Morant S. The cost-effectiveness of celecoxib compared with conventional NSAIDS in the treatment of arthritis. Intern Med J 2003; 33 Suppl: A84.